Stimulus-Funded CER: Few Awards Are For Drug Vs. Drug Studies
Pitting one drug against another proved not to be a key focus of the comparative effectiveness research funding given from the $1.1 billion set aside for CER in the American Recovery and Reinvestment Act.
You may also be interested in...
The Energy and Commerce Committee's investigation is an example of the close scrutiny of CER activities expected of the Republican-controlled House.
Pharmaceutical companies are going to need to consider the impact of the growing emphasis on comparative effectiveness earlier in the drug development and investment decision process, Merck & Co.'s Newell McElwee said.
Both the Institute of Medicine and the Federal Coordinating Council for Comparative Effectiveness Research are placing a high priority on building an infrastructure around comparative effectiveness to facilitate the research as well as the dissemination of findings